Literature DB >> 28648647

In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae.

Wei Yu1, Ping Shen1, Zhang Bao2, Kai Zhou1, Beiwen Zheng1, Jinru Ji1, Lihua Guo1, Chen Huang1, Yonghong Xiao3.   

Abstract

The increasing prevalence of KPC-producing Klebsiella pneumoniae (KPC-Kp) strains poses a serious threat to patients. Therapeutic options are limited to colistin, fosfomycin, tigecycline and selected aminoglycosides. Although the combination of fosfomycin with other antimicrobials is recommended, data regarding possible synergistic activity in vitro and in vivo appear inconsistent. Here we report that five drug combinations (fosfomycin combined with imipenem, ertapenem, tigecycline, colistin or amikacin) had a significant additive effect against 136 KPC-Kp strains in an in vitro chequerboard assay. In addition, time-kill assays revealed that fosfomycin enhanced the bactericidal activity of the five other antimicrobial agents. Moreover, owing to its persistent bactericidal effect, the combination of fosfomycin plus amikacin is an effective therapeutic candidate for infections by KPC-producing organisms.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bactericidal effect; Combination therapy; Fosfomycin; KPC-producing Klebsiella pneumoniae; Synergistic effect

Mesh：

Substances：

Year:  2017        PMID： 28648647     DOI： 10.1016/j.ijantimicag.2017.03.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  12 in total

Review 1.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

2.  Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors:  I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

Review 3.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

4.  Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6')-Ib.

Authors:  David A Butler; Amisha P Rana; Fiorella Krapp; Shitalben R Patel; Yanqin Huang; Egon A Ozer; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

5.  Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.

Authors:  Ahmed Megahed Abouwarda; Tarek Abdelmonem Ismail; Wael Mohamed Abu El-Wafa; Ahmed Hassan Ibrahim Faraag
Journal:  World J Microbiol Biotechnol       Date:  2022-04-29       Impact factor: 4.253

6.  In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae.

Authors:  Wei Yu; Qixia Luo; Qingyi Shi; Chen Huang; Xiao Yu; Tianshui Niu; Kai Zhou; Jiajie Zhang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-04-24       Impact factor: 4.003

7.  Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing Klebsiella pneumoniae Clinical Strains.

Authors:  Tania Cebrero-Cangueiro; Gema Labrador-Herrera; Álvaro Pascual; Caridad Díaz; Jesús Rodríguez-Baño; Jerónimo Pachón; José P Del Palacio; María E Pachón-Ibáñez; M Carmen Conejo
Journal:  Front Med (Lausanne)       Date:  2021-03-26

8.  Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.

Authors:  Guoan Wang; Wei Yu; Yushan Cui; Qingyi Shi; Chen Huang; Yonghong Xiao
Journal:  BMC Infect Dis       Date:  2021-03-26       Impact factor: 3.090

9.  In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci.

Authors:  Jiepeng Tong; Yiheng Jiang; Hao Xu; Xuehang Jin; Li Zhang; Shuaibing Ying; Wei Yu; Yunqing Qiu
Journal:  Drug Des Devel Ther       Date:  2021-07-12       Impact factor: 4.162

10.  Analysis of Genetic Diversity and Antibiotic Options for Clinical Listeria monocytogenes Infections in China.

Authors:  Wei Yu; Yicheng Huang; Chaoqun Ying; Yanzi Zhou; Li Zhang; Jiajie Zhang; Yingsha Chen; Yunqing Qiu
Journal:  Open Forum Infect Dis       Date:  2021-04-09       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.